Supernus Pharma (SUPN) Reports Q4 EPS of $0.04

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.04, versus $0.57 reported last year. Revenue for the quarter came in at $159.1 million, versus $143.6 million reported last year.

GUIDANCE:

Supernus Pharma sees FY2022 revenue of $640-680 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters